FPC
VKTX icon

Falcon Point Capital’s Viking Therapeutics VKTX Stock Holding History

Falcon Point Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-118,549
Closed -$1.18M – 110
2019
Q1 		$1.18M Buy
118,549
+2,395
+2% +$20K 0.64% 47
2018
Q4 		$889K Sell
116,154
-92,661
-44% -$1.11M 0.53% 49
2018
Q3 		$3.64M Buy
208,815
+191,891
+1,134% +$2.28M 0.78% 50
2018
Q2 		$161K Buy
+16,924
New +$113K 0.03% 115

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Falcon Point Capital's VKTX Position: Q2 2019 in Review

Falcon Point Capital sold out of Viking Therapeutics (VKTX) in Q2 2019, closing a stake of 118,549 shares — an estimated $1.18M sold.

Falcon Point Capital first reported a position in VKTX in Q2 2018 and held it in 4 quarters. The position peaked at $3.64M in Q3 2018. 156 funds tracked by Wall St. Rank hold VKTX as of Q2 2019.

  • Falcon Point Capital reported no remaining Viking Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Falcon Point Capital sold 118,549 Viking Therapeutics shares in Q2 2019, an estimated $1.18M.
  • Falcon Point Capital first reported a position in Viking Therapeutics in Q2 2018 and held it in 4 quarters.
  • Falcon Point Capital's Viking Therapeutics position peaked at $3.64M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2019.

Based on Falcon Point Capital's 13F filing for Q2 2019, filed 15 Jul 2019.